True under the assumption that they have identified predictive biomarkers. Not clear that cyclin D1 amplification and/or p16 loss actually add as selection markers on top of ER+/HER2–. Here are part 1 results:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.